AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05497375 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Surgeon Satisfaction
Description: Surgeon Satisfaction will be measured on a grade of 0-5 (1= very bad, 2= bad, 3= moderate, 4= good, 5= very good).
Study NCT05497375 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Heart rate
Description: From beginning of Anesthesia induction to the end of anesthesia (during perioperative period)
Study NCT05497375 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Mean arterial pressure
Description: From beginning of Anesthesia induction to the end of anesthesia (during perioperative period)
Study NCT05497375 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Peripheral oxygen saturation
Description: From beginning of Anesthesia induction to the end of anesthesia (during perioperative period)
Study NCT05499702 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Caloric Restriction
Description: Subjects will be instructed to consume a diet of 900 kcal daily using meals derived from Nutritional Guidelines after Bariatric Surgery. Compliance will be monitored by weekly meetings with the dietician using an electronic record of food intake
Study NCT05499702 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperglycemic clamp
Description: Hyperglycemic clamp to measure the effect of glucagon on hepatic metabolism
Study NCT03382249 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Sonodynamic therapy (SDT)
Description: Sonodynamic therapy(SDT) treatment is the combination of sonosensitizer administration and target atherosclerotic lesions ultrasound exposure. Sinoporphyrin sodium (DVDMS) as sonosensitizer, is dissolved in 0.9% sodium solution for following skin test and intravenous injection. 0.01mg/ml DVDMS solution (0.1ml) is prepared for skin test followed by 0.04 mg/ml DVDMS solution intravenous injection (0.2mg/kg).The target atherosclerotic lesions are marked on the corresponding skin with ultrasound guidance and underwent ultrasound exposure after 4 hours incubation. The therapeutic ultrasonic transducer is fixed to the marked skin site for 15min of each lesion. Ultrasound parameters included intensity of 1.6W/cm2 for carotid lesions, resonance frequency: 1.0 MHz and duty factor: 30%.
Study NCT03382249 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: pseudo-SDT
Description: Pseudo-SDT combines saline injection and obstructed ultrasound exposure on targeted lesions to simulate real SDT progression.
Study NCT04882982 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Caria app
Description: App to improve symptoms of menopause
Study NCT04882982 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Menopause Education
Description: Educational materials about symptoms of menopause
Study NCT05681754 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Experimental: RCT using hydraulic calcium silicate sealer and L-PRF + GTR
Description: Endodontic treatment with hydraulic calcium silicate sealer, followed by periodontal surgery using GTR +/- LPRF
Study NCT05681754 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Experimental: RCT using conventional sealer and L-PRF + GTR
Description: Endodontic treatment with conventional sealer followed by periodontal treatment with PRF + GTR
Study NCT05681754 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Experimental: RCT using hydraulic calcium silicate sealer and GTR
Description: Endodontic treatment with hydraulic calcium silicate sealer, followed by periodontal surgery using GTR only
Study NCT05681754 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator: RCT using conventional sealer and GTR (bone substitute + collagen membrane)
Description: Endodontic treatment with conventional sealer followed by periodontal treatment with GTR only
Study NCT04618978 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: PSG and actigraphy recording
Description: Gold standard: electromyographic recording of tibialis anterior muscle during full night polysomnography (PSG).~The new generation actigraphs devices Actiwatch will be combined to PSG as a screening tool: MotionWatch will be placed on the dorsum of feet to record).
Study NCT06271902 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Singapore Youth Shoulder Overuse Injury Prevention Program
Description: A 10-minute, 4-exercises program that targets shoulder eccentric external rotation strength, shoulder internal rotation range of morion, and thoracic rotation range of motion. The topic for the 45-minute educational workshop will be on overuse injuries among youth athletes.
Study NCT06271902 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lower body stretching program
Description: A 10-minute, 5-stretches sham exercise program that does not target the upper extremity and are only held for 10 seconds.
Study NCT05899322 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Primary Care Intervention for PTSD Spanish Speaking Adolescents
Description: This treatment ranges from 1-3 sessions which last 30-50 minutes per session. The first session will cover psychoeducation about PTSD symptoms in children that can be delivered to the adolescent with optional parent involvement. The first session will also teach the adolescent a breathing technique to combat the physiological impact of PTSD in children. The subsequent sessions will be tailored to meet the needs of the adolescent's most distressing PTSD symptom cluster including hyper arousal, negative changes in cognition and mood, avoidance, re-experiencing. Each session contains coping skills that address the adolescent's symptoms. This treatment will be delivered via telehealth and all materials have been developed in both Spanish and English.
Study NCT05899322 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Waitlist Treatment as Usual
Description: Will receive treatment as usual at local clinic and are provided information on free or low cost mental health care referrals in the Los Angeles Area.
Study NCT06262139 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT218 injection
Description: a targeted magnetic resonance imaging contrast agent
Study NCT06241235 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZG005 Powder for Injection
Description: ZG005 for dose escalations are set as 10 mg/kg, 15 mg/kg and other doses after discussion, intravenous infusion(IV), once every 3 weeks (Q3W). ZG005 for dose-expansion stage will commence after the Recommended Phase 2 Dose (RP2D) is determined during the dose-escalation stage.
Study NCT06241235 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: IV infusion
Study NCT06241235 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: IV infusion
Study NCT06241235 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: IV infusion
Study NCT06241235 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: IV infusion
Study NCT06439901 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Screening
Description: A first step to identify and recruit people eligible for screening,
Study NCT06439901 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Inclusion
Description: A second step for inclusion of participants, with an online self-questionnaire and information, and an inclusion visit to the health center,
Study NCT06439901 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Chest CTscan and follow-up
Description: A third step with an initial CTscan, with dual interpretation and appropriate management of participants, including follow-up care.
Study NCT04908371 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Selective Trunk Block
Description: It is one type of peripheral nerve blocks for upper extremity surgery. Patients will have an ultrasound scan and nerve block with local anesthetic (LA) agent (a mixture of 2% Xylocaine with 1:200,000 adrenaline and 0.5% Chirocaine in a total of 20ml) injected at the trunks of the brachial plexus in order to produce the anesthesia of the whole upper extremity of the patients scheduled for upper limb surgery. SeTB will be performed as a two-injection technique. One at the side of the neck (interscalene groove) of the affected upper limb, injections will be made near the superior trunk (5mL) and follow by redirection of the needle under ultrasound guidance to inject the LA to middle trunk (5mL). Then the second skin puncture will be made near the upper part mid-collar bone (supraclavicular fossa) to inject the LA to the inferior trunk (10mL).
Study NCT04908371 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Interscalene-Supraclavicular Brachial Plexus Block (IS-SC BPB)
Description: It is another type of peripheral nerve blocks for upper extremity surgery. Patients will have an ultrasound scan and nerve block with local anesthetic (LA) agent (a mixture of 2% Xylocaine with 1:200,000 adrenaline and 0.5% Chirocaine in a total of 30ml) injected at the interscalene groove and supraclavicular fossa, so two-injection technique will be adopted. The first skin puncture will be near the side of the neck (interscalene groove) of the affected upper limb (15mL) and then the second skin puncture will also be made near the upper mid-collar bone (supraclavicular fossa) to inject 15mL of LA.
Study NCT05680779 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ultrasound-guided percutaneous neuromodulation
Description: It´s an intervention of physiotherapy
Study NCT05680779 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: dry needling
Description: It´s an intervention of physiotherapy
Study NCT06367036 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Topical hypericum perforatum oil intervention
Description: The research nurse working in the CICU applied 5-6 drops of hypericum perforatum oil on one arm of the patient with a patting motion 2 hours before the injection. The area was left open for the oil to be absorbed. Only this nurse who administered the injection knows on which arm the oil was applied.
Study NCT04776057 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: catarct surgery with toric intra ocular lenses
Description: rotation stability of toric intraocular lenses between sitting or routine settings (sitting, going around) after cataract operation
Study NCT05500092 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nivolumab
Description: Patients randomized to the Nivolumab + Platinum Doublet Chemotherapy only arm will receive three cycles of nivolumab at a dose of 360 mg every three weeks along with a platinum-based chemotherapy doublet (cisplatin or carboplatin plus pemetrexed for adenocarcinoma, cisplatin or carboplatin plus docetaxel, paclitaxel, or gemcitabine for squamous NSCLC) with sub-ablative stereotactic radiation therapy (8 Gy x 3) directed at the primary lung tumor
Study NCT05500092 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Patients randomized to the Nivolumab + Platinum Doublet Chemotherapy only arm will receive three cycles of nivolumab at a dose of 360 mg every three weeks along with a platinum-based chemotherapy doublet (cisplatin or carboplatin plus pemetrexed for adenocarcinoma, cisplatin or carboplatin plus docetaxel, paclitaxel, or gemcitabine for squamous NSCLC) with sub-ablative stereotactic radiation therapy (8 Gy x 3) directed at the primary lung tumor
Study NCT05500092 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: (8gy x 3)
Description: sub-ablative stereotactic radiation therapy (8 Gy x 3) directed at the primary lung tumor
Study NCT05500092 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Platinum Doublet
Description: Standard of care doublet platinum therapy
Study NCT05509842 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS
Description: A MagPro X100 magnetic stimulator with a 90mm figure-8 coil (MC-B70, MagVenture Inc.) will be used to apply rTMS to targeted locations marked on the structural MRI using a frameless infrared stereotactic neuronavigation system (Brainsight, Rogue Research).
Study NCT05317910 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MUSIC CARE
Description: Relaxation-type receptive musical intervention technique. The standardized 20-minute musical sequence is broken down into several phases that gradually lead the patient to relaxation using the new U-Mount technique \[1, 2\] (Figure 1). The effect works by reducing the musical rhythm, orchestral formation, frequencies and volume (the U descending phase). After a maximum relaxation phase (lower part of the U), a re-activating phase (ascending branch of the U) is followed.
Study NCT04360681 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lofexidine
Description: BID dosing, and a max daily dose of 1.6 mg/day
Study NCT04360681 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Placebo
Study NCT05500092 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Platinum Doublet
Description: Standard of care doublet platinum therapy
Study NCT05201976 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Virtually administered Cardiac Rehab program
Description: Virtual cardiac rehab program delivered through the CardaHealth platform.
Study NCT05201976 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care in person Cardiac Rehab Program
Description: Clinically ordered standard of care cardiac rehab program (in-person).
Study NCT06111079 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aspirin discontinuation
Description: Initiation of aspirin 100mg qn from 12 to 16 weeks of gestation, discontinuing aspirin at 28 weeks of gestation according to randomization at 24-27+6 weeks of gestation.
Study NCT06111079 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: aspirin continuation
Description: Initiation of aspirin 100mg qn from 12 to 16 weeks of gestation, continuing aspirin until 36 weeks of gestation according to randomization at 24-27+6 weeks of gestation.
Study NCT05800639 — intervention group
Intervention type: PROCEDURE
Intervention: Ophthalmic surgery
Description: Ophthalmic surgery will be performed as standard practice of our institution.
Study NCT05800639 — intervention group
Intervention type: PROCEDURE
Intervention: General anesthesia
Description: General anesthesia will be performed as standard practice of our institution.
Study NCT05657730 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Water Kefir beverage
Description: Participants will consume the water kefir beverage for two weeks.
Study NCT04745208 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Simulation based education
Description: high fidelity simulation with moulage
Study NCT05009368 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug: Treatment A
Description: CTL0901, single dose, daily, repeated oral administration for 4 days
Study NCT05009368 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug: Treatment B
Description: CTL0902, single dose, daily, repeated oral administration for 7 days
Study NCT05009368 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug: Treatment C
Description: CTL0901 and CTL0902, single dose, daily, repeated oral administration for 7 days
Study NCT06208826 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: Toripamab, IV, 240mg, every 3 weeks for 15 cycles
Study NCT06208826 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation Therapy
Description: Radiation Therapy
Study NCT06208826 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Chemotherapy agent
Study NCT05663060 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Probiotic Formula
Description: Probiotic Formula
Study NCT04800692 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tetrahydrobiopterin 10 mg/kg
Description: 10mg/kg of Tetrahydrobiopterin daily.
Study NCT04800692 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tetrahydrobiopterin 20 mg/kg
Description: 20mg/kg of Tetrahydrobiopterin daily.
Study NCT04800692 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-Ascorbate
Description: 3300 mg of l-ascorbate once daily
Study NCT04800692 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-Arginine
Description: 3400mg of l-arginine once daily
Study NCT04908293 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biorepair toothpaste
Description: Use of New Biorepair Advanced Sensitive for home oral care.
Study NCT04908293 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Colgate toothpaste
Description: Use of Colgate toothpaste for home oral care.
Study NCT06511583 — intervention group
Intervention type: PROCEDURE
Intervention: Laryngotracheal Aspiration Procedure Using a Probe in the Emergency Department
Description: For laryngotracheal aspiration using a blind probe, the patient will be positioned in a seated or semi-seated position; if this is not possible, the aspiration will be performed in a supine position. A soft, sterile catheter connected to the suction apparatus will be inserted into one nostril while keeping the patient\&#39;s head tilted back. When the tip of the catheter reaches the back of the pharynx, the patient will need to breathe to facilitate the insertion and allow the catheter to advance into the larynx and trachea. At this point, using negative suction pressure for a maximum of 3-5 seconds, the secretions will be aspirated. The aspiration will be repeated multiple times in cycles of 3-5 seconds.
Study NCT06511583 — intervention group
Intervention type: PROCEDURE
Intervention: Aspiration Procedure Using Fibrobronchoscopy in the Emergency Department
Description: Equipment Setup:~A sterile bronchoscope will be connected to the suction apparatus.~Procedure:~The bronchoscope will be gently inserted through the patient\&#39;s nostril or mouth, advancing carefully through the pharynx and larynx into the trachea and bronchi.~The physician will visually inspect the airways through the bronchoscope. Using the bronchoscope's suction channel, secretions will be aspirated from the trachea and bronchi.~Suctioning will be performed intermittently to avoid hypoxia, with each suctioning cycle lasting no more than 3-5 seconds.~The procedure may be repeated as necessary to ensure thorough aspiration of secretions.
Study NCT06157073 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Closed-loop ventilator
Description: Fully automated closed-loop ventilator using the INTELLIVENT software
Study NCT06157073 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Open-loop ventilator
Description: Conventional closed-loop ventilator with manual adjustments by the physician in charge
Study NCT06442982 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: insole-type gait analyzer
Description: Patients with subjective gait and balance disorders will wear insole-type gait analyzer and walk, then the collected data will be examined.
Study NCT05505799 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intubation Checklist
Description: A preprocedure checklist will be made available to clinicians, and they will be educated on proper use of the checklist
Study NCT05505799 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: Clinicians will intubate as per their usual practice
Study NCT04893213 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manipulation of availability of lower energy meal options
Description: Menus provided differ in % of menu options that are higher vs. lower in energy
Study NCT04893213 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manipulation of availability of lower energy meal options
Description: Menus provided differ in % of menu options that are higher vs. lower in energy
Study NCT06093217 — intervention group
Intervention type: DEVICE
Intervention: Artificial Intelligence
Description: AI technology will generate a report with relevant key slice imaging identifying the presence of an acute pulmonary embolism and RV:LV ratio measurements to the radiologist
Study NCT06014710 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Swallowing evaluation
Description: For patients with swallowing disorders: assessment of the swallowing performed according to the available reference examination (videofluoroscopy or nasofibroscopy). In parallel, they will carry the following sensors: microphone, accelerometer, surface electromyography, nasal cannula and pulse oximeter. The subjects will also perform a cough and phonation test and questionnaires. Each subject (or his caregiver) will be contacted by phone once a month for 6 months to monitor the occurrence of complications. The end of study visit at 6 months will be done either at the hospital with a new examination of the swallowing, by telephone, as medically indicated.~For healthy volunteers: Only one visit is planned for the evaluation of the swallowing with the examination of nasofibroscopy and the installation of the sensors. The procedures (tests, examinations and questionnaires) will be identical to the data collection of the initial visit of patients with swallowing disorders)
Study NCT04774341 — intervention group
Intervention type: DRUG
Intervention: anticoagulation treatment
Description: Adherence to personalized evidence-based anticoagulant treatment in patients at high risk for stroke with atrial fibrillation
Study NCT04677855 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PCUR-101
Description: 50 mg capsules
Study NCT04677855 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dutasteride 0.5 mg
Description: 0.5 mg capsules
Study NCT04677855 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone and Prednisone
Description: 500 mg tablets Abiraterone with 5 mg Prednisone Tablets
Study NCT05750147 — intervention group
Intervention type: OTHER
Intervention: Blood Sample Collection
Description: Blood for DNA and biomarker analysis